首页 > 最新文献

Profiles of drug substances, excipients, and related methodology最新文献

英文 中文
Bisoprolol: A comprehensive profile. 比索洛尔:一个全面的档案。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2021-01-01 Epub Date: 2020-09-08 DOI: 10.1016/bs.podrm.2020.07.006
Ahmed H Bakheit, Raisuddin Ali, Ali D Alshahrani, Adel S El-Azab

The present study describes a comprehensive profile of Bisoprolol including detailed nomenclature; formulae, elemental analysis, appearance, its uses, applications, and methods for the preparation are outlined. The profile contains physicochemical properties of Bisoprolol including pKa value, solubility, X-ray powder diffraction, and methods of analysis (including compendial, electrochemical, spectroscopic, chromatographic and capillary electrophoresis). The study also covers thermal analysis such as differential scanning calorimetry and thermogravimetry of Bisoprolol. Which gives a brief idea of melting point, glass transition as well as differentiation between anhydrous and hydrated forms. In addition to these functional groups and structural confirmation of bisoprolol also presented with the help of Fourier transform infrared spectrometry and nuclear magnetic resonance spectroscopy, respectively. The mass fragmentation pattern of bisoprolol fumarate was reported using the electrospray ionization technique. Some recently reported methods for pharmacokinetic analysis of bisoprolol using high-performance liquid chromatography as well as liquid chromatography-mass spectrometry were also included in the study.

本研究描述了比索洛尔的全面概况,包括详细的命名法;概述了配方、元素分析、外观、用途、应用和制备方法。该剖面包含比索洛尔的理化性质,包括pKa值、溶解度、x射线粉末衍射和分析方法(包括药理学、电化学、光谱、色谱和毛细管电泳)。本研究还涵盖了比洛尔的热分析,如差示扫描量热法和热重法。它简要介绍了熔点,玻璃化转变以及无水和水合形式的区别。此外,还分别利用傅里叶变换红外光谱和核磁共振光谱对比索洛尔的官能团和结构进行了确证。采用电喷雾电离技术研究了富马酸比索洛尔的质量破碎模式。本文还介绍了近年来报道的高效液相色谱和液相色谱-质谱联用分析比索洛尔药代动力学的方法。
{"title":"Bisoprolol: A comprehensive profile.","authors":"Ahmed H Bakheit,&nbsp;Raisuddin Ali,&nbsp;Ali D Alshahrani,&nbsp;Adel S El-Azab","doi":"10.1016/bs.podrm.2020.07.006","DOIUrl":"https://doi.org/10.1016/bs.podrm.2020.07.006","url":null,"abstract":"<p><p>The present study describes a comprehensive profile of Bisoprolol including detailed nomenclature; formulae, elemental analysis, appearance, its uses, applications, and methods for the preparation are outlined. The profile contains physicochemical properties of Bisoprolol including pKa value, solubility, X-ray powder diffraction, and methods of analysis (including compendial, electrochemical, spectroscopic, chromatographic and capillary electrophoresis). The study also covers thermal analysis such as differential scanning calorimetry and thermogravimetry of Bisoprolol. Which gives a brief idea of melting point, glass transition as well as differentiation between anhydrous and hydrated forms. In addition to these functional groups and structural confirmation of bisoprolol also presented with the help of Fourier transform infrared spectrometry and nuclear magnetic resonance spectroscopy, respectively. The mass fragmentation pattern of bisoprolol fumarate was reported using the electrospray ionization technique. Some recently reported methods for pharmacokinetic analysis of bisoprolol using high-performance liquid chromatography as well as liquid chromatography-mass spectrometry were also included in the study.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"46 ","pages":"51-89"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2020.07.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38833684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Darunavir: A comprehensive profile. Darunavir:一个全面的简介。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2021-01-01 Epub Date: 2020-08-21 DOI: 10.1016/bs.podrm.2020.07.001
Ibrahim A Darwish, Abdulrahman A Al-Majed, Nawaf A Alsaif, Ahmed H Bakheit, Rashed N Herqash, Abdullah Alzaid

Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]carbamate is a synthetic non-peptide protease inhibitor. On June 2006, it was first approved by the Food and Drug administration (FDA) for treatment of resistant type-1 of the human immunodeficiency virus (HIV). In July 2016, the FDA expanded the approval for use of darunavir in pregnant women with HIV infection. Darunavir prevents the replication of HIV virus by inhibiting the catalytic activity of the HIV-1 protease enzyme, and selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus-infected cells, which prevents the formation of mature infectious virus particles. Darunavir is unique among currently available protease inhibitors because it maintains antiretroviral activity against a variety of multidrug-resistant HIV strains. This article discusses, by a critical extensive review of the literature, the description of darunavir in terms of its names, formulae, elemental composition, appearance, and use in the treatment of HIV-infected patients. The article also discusses the methods for preparation of darunavir, its physical-chemical properties, analytical methods for its determination, pharmacological properties, and dosing information.

Darunavir: (3R,3aS,6aR)-六氢呋喃[2,3-b]呋喃-3-基[(2S,3R)-4-{[(4-氨基苯基)磺酰](异丁基)氨基}-3-羟基-1-苯基-2-丁基]氨基甲酸酯是一种合成的非肽蛋白酶抑制剂。2006年6月,它首次被美国食品和药物管理局(FDA)批准用于治疗耐药1型人类免疫缺陷病毒(HIV)。2016年7月,FDA扩大了darunavir在感染HIV的孕妇中使用的批准。Darunavir通过抑制HIV-1蛋白酶的催化活性来阻止HIV病毒的复制,并选择性地抑制病毒感染细胞中HIV编码的Gag-Pol多蛋白的裂解,从而阻止成熟感染性病毒颗粒的形成。Darunavir在目前可用的蛋白酶抑制剂中是独一无二的,因为它对多种多重耐药的HIV毒株保持抗逆转录病毒活性。本文通过对文献的批判性广泛回顾,讨论了darunavir在其名称、配方、元素组成、外观和在治疗hiv感染患者中的使用方面的描述。本文还讨论了达那韦的制备方法、理化性质、测定方法、药理学性质和给药情况。
{"title":"Darunavir: A comprehensive profile.","authors":"Ibrahim A Darwish,&nbsp;Abdulrahman A Al-Majed,&nbsp;Nawaf A Alsaif,&nbsp;Ahmed H Bakheit,&nbsp;Rashed N Herqash,&nbsp;Abdullah Alzaid","doi":"10.1016/bs.podrm.2020.07.001","DOIUrl":"https://doi.org/10.1016/bs.podrm.2020.07.001","url":null,"abstract":"<p><p>Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]carbamate is a synthetic non-peptide protease inhibitor. On June 2006, it was first approved by the Food and Drug administration (FDA) for treatment of resistant type-1 of the human immunodeficiency virus (HIV). In July 2016, the FDA expanded the approval for use of darunavir in pregnant women with HIV infection. Darunavir prevents the replication of HIV virus by inhibiting the catalytic activity of the HIV-1 protease enzyme, and selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus-infected cells, which prevents the formation of mature infectious virus particles. Darunavir is unique among currently available protease inhibitors because it maintains antiretroviral activity against a variety of multidrug-resistant HIV strains. This article discusses, by a critical extensive review of the literature, the description of darunavir in terms of its names, formulae, elemental composition, appearance, and use in the treatment of HIV-infected patients. The article also discusses the methods for preparation of darunavir, its physical-chemical properties, analytical methods for its determination, pharmacological properties, and dosing information.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"46 ","pages":"1-50"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2020.07.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38833681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Irbesartan (a comprehensive profile). 厄贝沙坦(综合概况)。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2021-01-01 Epub Date: 2020-08-21 DOI: 10.1016/bs.podrm.2020.07.004
Ibrahim A Darwish, Hany W Darwish, Ahmed H Bakheit, Hamad M Al-Kahtani, Zahi Alanazi

Irbesartan, (2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one), is a member of non-peptide angiotensin II receptor antagonists used worldwide in the treatment of hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. Irbesartan can be used alone or in combination with other antihypertensive agents (e.g., hydrochlorothiazide). These combination products are indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy. Irbesartan is also indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension, an elevated serum creatinine, and proteinuria. Irbesartan exerts its action mainly via a selective blockade action on AT1 receptors and the consequent reduced pressor effect of angiotensin II. This article discusses, by a critical comprehensive review of the literature on irbesartan in terms of its description, names, formulae, elemental composition, appearance, and therapeutic uses. The article also discusses the methods for preparation of irbesartan, its physical-chemical properties, analytical methods for its determination, pharmacological-toxicological properties, and dosing information.

厄贝沙坦(2-丁基-3-({4-[2-(2h -1,2,3,4-四唑-5-基)苯基]苯基}甲基)-1,3-重氮斯匹罗[4.4]非1-en-4- 1)是一种非肽血管紧张素II受体拮抗剂,用于治疗高血压和糖尿病肾病合并2型糖尿病、血清肌酐升高和蛋白尿的高血压患者。厄贝沙坦可单独使用或与其他抗高血压药物(如氢氯噻嗪)联合使用。这些联合产品适用于单药未控制的高血压患者或单药不能很好控制的一线高血压患者。厄贝沙坦也适用于治疗伴有2型糖尿病和高血压、血清肌酐升高和蛋白尿的糖尿病肾病患者。厄贝沙坦主要通过选择性阻断AT1受体发挥作用,从而降低血管紧张素II的降压作用。本文通过对厄贝沙坦的描述、名称、配方、元素组成、外观和治疗用途等方面的文献进行了批判性的综合综述。本文还介绍了厄贝沙坦的制备方法、理化性质、测定方法、药理学、毒理学性质和给药情况。
{"title":"Irbesartan (a comprehensive profile).","authors":"Ibrahim A Darwish,&nbsp;Hany W Darwish,&nbsp;Ahmed H Bakheit,&nbsp;Hamad M Al-Kahtani,&nbsp;Zahi Alanazi","doi":"10.1016/bs.podrm.2020.07.004","DOIUrl":"https://doi.org/10.1016/bs.podrm.2020.07.004","url":null,"abstract":"<p><p>Irbesartan, (2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one), is a member of non-peptide angiotensin II receptor antagonists used worldwide in the treatment of hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. Irbesartan can be used alone or in combination with other antihypertensive agents (e.g., hydrochlorothiazide). These combination products are indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy. Irbesartan is also indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension, an elevated serum creatinine, and proteinuria. Irbesartan exerts its action mainly via a selective blockade action on AT1 receptors and the consequent reduced pressor effect of angiotensin II. This article discusses, by a critical comprehensive review of the literature on irbesartan in terms of its description, names, formulae, elemental composition, appearance, and therapeutic uses. The article also discusses the methods for preparation of irbesartan, its physical-chemical properties, analytical methods for its determination, pharmacological-toxicological properties, and dosing information.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"46 ","pages":"185-272"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2020.07.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38833682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Betaxolol: A comprehensive profile. 倍他洛尔:一个全面的概况。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2021-01-01 Epub Date: 2020-08-21 DOI: 10.1016/bs.podrm.2020.07.002
Majed J Al-Wadei, Ahmed H Bakheit, Alaa A-M Abdel-Aziz, Tanveer A Wani

Betaxolol is a relatively cardioselective β-adrenoceptor blocking drug, with no partial agonist (intrinsic sympathomimetic) activity and weak membrane-stabilizing (local anesthetic) activity. Betaxolol selectively and competitively binds to and blocks beta-1 (β1) adrenergic receptors in the heart, thereby decreasing cardiac contractility and rate. This leads to a reduction in cardiac output and lowers blood pressure. When applied topically in the eye, this agent reduces aqueous humor secretion and lowers the intraocular pressure (IOP). In addition, betaxolol prevents the release of renin, a hormone secreted by the kidneys that causes constriction of blood vessels. Betaxolol (S)-(-)-enantiomer shows higher pharmacological activity. This chapter provides a complete review of nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of betaxolol. In addition, the chapter also includes review of several methods for enantiomeric separation betaxolol using chromatographic techniques.

倍他洛尔是一种相对具有心脏选择性的β-肾上腺素能受体阻断药物,没有部分激动剂(内在拟交感神经)活性和弱的膜稳定(局部麻醉)活性。倍他洛尔选择性和竞争性地结合并阻断心脏β -1 (β1)肾上腺素能受体,从而降低心脏收缩力和速率。这会导致心输出量减少,降低血压。当局部应用于眼睛时,该药物可减少房水分泌并降低眼压(IOP)。此外,倍他洛尔还能阻止肾素的释放,肾素是由肾脏分泌的一种导致血管收缩的激素。倍他洛尔(S)-(-)-对映体具有较高的药理活性。本章对倍他洛尔的命名、理化性质、制备方法、鉴定技术、各种定性和定量分析技术以及药理等方面进行了综述。此外,本章还包括几种使用色谱技术分离倍他洛尔对映体的方法。
{"title":"Betaxolol: A comprehensive profile.","authors":"Majed J Al-Wadei,&nbsp;Ahmed H Bakheit,&nbsp;Alaa A-M Abdel-Aziz,&nbsp;Tanveer A Wani","doi":"10.1016/bs.podrm.2020.07.002","DOIUrl":"https://doi.org/10.1016/bs.podrm.2020.07.002","url":null,"abstract":"<p><p>Betaxolol is a relatively cardioselective β-adrenoceptor blocking drug, with no partial agonist (intrinsic sympathomimetic) activity and weak membrane-stabilizing (local anesthetic) activity. Betaxolol selectively and competitively binds to and blocks beta-1 (β1) adrenergic receptors in the heart, thereby decreasing cardiac contractility and rate. This leads to a reduction in cardiac output and lowers blood pressure. When applied topically in the eye, this agent reduces aqueous humor secretion and lowers the intraocular pressure (IOP). In addition, betaxolol prevents the release of renin, a hormone secreted by the kidneys that causes constriction of blood vessels. Betaxolol (S)-(-)-enantiomer shows higher pharmacological activity. This chapter provides a complete review of nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of betaxolol. In addition, the chapter also includes review of several methods for enantiomeric separation betaxolol using chromatographic techniques.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"46 ","pages":"91-136"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38832186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Preface. 前言。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2021-01-01 DOI: 10.1016/S1871-5125(21)00009-1
Abdulrahman A Al-Majed
{"title":"Preface.","authors":"Abdulrahman A Al-Majed","doi":"10.1016/S1871-5125(21)00009-1","DOIUrl":"https://doi.org/10.1016/S1871-5125(21)00009-1","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"46 ","pages":"ix-x"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1871-5125(21)00009-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38832187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Copyright 版权
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 DOI: 10.1016/s1871-5125(20)30006-6
{"title":"Copyright","authors":"","doi":"10.1016/s1871-5125(20)30006-6","DOIUrl":"https://doi.org/10.1016/s1871-5125(20)30006-6","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s1871-5125(20)30006-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56842832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profiles of Drug Substances, Excipients, and Related Methodology 原料药、赋形剂和相关方法学简介
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 DOI: 10.1016/S1075-6280(02)29002-3
H. Brittain
{"title":"Profiles of Drug Substances, Excipients, and Related Methodology","authors":"H. Brittain","doi":"10.1016/S1075-6280(02)29002-3","DOIUrl":"https://doi.org/10.1016/S1075-6280(02)29002-3","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-6280(02)29002-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56387938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 414
Carbetapentane citrate. 柠檬酸卡贝塔戊烷。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 Epub Date: 2019-12-05 DOI: 10.1016/bs.podrm.2019.10.002
Ahmed S Abo Dena, Alaa M Ali, Ibrahim M El-Sherbiny

Carbetapentane citrate, a non-opioid centrally-acting antitussive drug, is a common treatment for cough associated with other diseases such as common cold and respiratory tract infections. Its mode of action is very close to that of atropine; since it acts at the level of the peripheral parasympathetic nerve endings. The drug reaches its maximum plasma concentration (Cmax) 2h after administration, and it has a plasma half-life of 2.3h in case of oral administration. Due to its clinical importance, there are many analytical methods in the literature for carbetapentane determination. In addition, it is crucial to collect its analytical results in a single chapter so as to allow researchers to easily interpret their experimental data. Here, we provide the analytical profile of carbetapentane citrate with a brief description/interpretation of each analysis.

柠檬酸卡丁戊烷是一种非阿片类药物中枢作用止咳药,是治疗与普通感冒和呼吸道感染等其他疾病相关的咳嗽的常用药物。它的作用方式与阿托品非常接近;因为它作用于外周副交感神经末梢。给药后2h达到最大血药浓度(Cmax),口服给药的半衰期为2.3h。由于其在临床中的重要性,文献中有许多测定碳戊烷的分析方法。此外,它是至关重要的收集其分析结果在一个单一的章节,使研究人员可以很容易地解释他们的实验数据。在这里,我们提供了柠檬酸碳戊烷的分析概况,并对每个分析进行了简要的描述/解释。
{"title":"Carbetapentane citrate.","authors":"Ahmed S Abo Dena,&nbsp;Alaa M Ali,&nbsp;Ibrahim M El-Sherbiny","doi":"10.1016/bs.podrm.2019.10.002","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.002","url":null,"abstract":"<p><p>Carbetapentane citrate, a non-opioid centrally-acting antitussive drug, is a common treatment for cough associated with other diseases such as common cold and respiratory tract infections. Its mode of action is very close to that of atropine; since it acts at the level of the peripheral parasympathetic nerve endings. The drug reaches its maximum plasma concentration (C<sub>max</sub>) 2h after administration, and it has a plasma half-life of 2.3h in case of oral administration. Due to its clinical importance, there are many analytical methods in the literature for carbetapentane determination. In addition, it is crucial to collect its analytical results in a single chapter so as to allow researchers to easily interpret their experimental data. Here, we provide the analytical profile of carbetapentane citrate with a brief description/interpretation of each analysis.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"45 ","pages":"41-53"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37731930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Azilsartan medoxomil. 阿齐沙坦酯钾。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 Epub Date: 2019-12-06 DOI: 10.1016/bs.podrm.2019.10.001
Abdulrahman A Al-Majed, Ahmed H H Bakheit, Ali Al-Muhsin, Hamad M Al-Kahtani, Ali S Abdelhameed

Azilsartan is used for treatment of the high blood pressure (hypertension). Reducing high blood pressure enables avoid strokes, heart attacks and problems of kidneys. Azilsartan comes under the name angiotensin receptor blocker (ARBs) as a class of drugs. It acts by relaxing blood vessels to make it easier for blood to flow. Azilsartan Medoxomil's a comprehensive profile containing the description, formulae, Elemental Analysis, Uses and application. Furthermore, methods and schemes are outlined for the preparation of the drug substance. The physical properties of the medication include constant of ionization, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal conduct and spectroscopic studies are investigated. The methods employed in bulk medicines and/or in pharmaceutical formulations to analyze the drug substance include spectrophotometric, electrochemical and the chromatographic methods. Other studies on this drug substance include drug stability, Pharmaceutical Applications, Mechanism of Action, Pharmacodynamics, and a Dosing Information are reviewed. At the end of this profile, there are more than sixty references were listed.

阿兹沙坦用于治疗高血压。降低高血压可以避免中风、心脏病发作和肾脏问题。阿兹沙坦被命名为血管紧张素受体阻滞剂(ARBs)作为一类药物。它的作用是放松血管,使血液更容易流动。阿兹沙坦美多索米是一个全面的介绍,包括描述,配方,元素分析,用途和应用。此外,还概述了该原料药的制备方法和方案。研究了药物的物理性质,包括电离常数、溶解度、x射线粉末衍射图、差示扫描量热、热传导和光谱研究。原料药和/或制剂中用于分析原料药的方法包括分光光度法、电化学法和色谱法。对该原料药的稳定性、药物应用、作用机制、药效学和给药信息等方面的研究进行了综述。在本概要的最后,列出了60多个参考文献。
{"title":"Azilsartan medoxomil.","authors":"Abdulrahman A Al-Majed,&nbsp;Ahmed H H Bakheit,&nbsp;Ali Al-Muhsin,&nbsp;Hamad M Al-Kahtani,&nbsp;Ali S Abdelhameed","doi":"10.1016/bs.podrm.2019.10.001","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.001","url":null,"abstract":"<p><p>Azilsartan is used for treatment of the high blood pressure (hypertension). Reducing high blood pressure enables avoid strokes, heart attacks and problems of kidneys. Azilsartan comes under the name angiotensin receptor blocker (ARBs) as a class of drugs. It acts by relaxing blood vessels to make it easier for blood to flow. Azilsartan Medoxomil's a comprehensive profile containing the description, formulae, Elemental Analysis, Uses and application. Furthermore, methods and schemes are outlined for the preparation of the drug substance. The physical properties of the medication include constant of ionization, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal conduct and spectroscopic studies are investigated. The methods employed in bulk medicines and/or in pharmaceutical formulations to analyze the drug substance include spectrophotometric, electrochemical and the chromatographic methods. Other studies on this drug substance include drug stability, Pharmaceutical Applications, Mechanism of Action, Pharmacodynamics, and a Dosing Information are reviewed. At the end of this profile, there are more than sixty references were listed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"45 ","pages":"1-39"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37732546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isotretinoin. 异维甲酸。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 Epub Date: 2019-12-06 DOI: 10.1016/bs.podrm.2019.10.005
Nasr Y Khalil, Ibrahim A Darwish, Abdulmohsen A Al-Qahtani

Isotretinoin is chemically named as: (2Z, 4E, 6E, 8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid. It is an orally active retinoic acid derivative for the treatment of severe refractory nodulocystic acne. It acts primarily by reducing sebaceous gland size and sebum production, and as a result alters skin surface lipid composition. Using isotretinoin for 1-2mg/kg/day for 3-4 months produces 60%-95% clearance of inflammatory lesions in patients with acne. Doses as low as 0.1mg/kg/day have also proven successful in the clearance of lesions. Encouraging results have also been seen in small numbers of patients with rosacea, Side effects affecting the mucocutaneous system and raised serum triglyceride levels occur in most patients receiving isotretinoin. Isotretinoin is strictly contraindicated in women of childbearing potential. This profile discusses and explains names of isotretinoin, its physical and chemical characteristics. It also includes methods of preparation, thermal and spectral behavior, methods of analysis, and pharmacology.

异维甲酸的化学名称为:(2Z, 4E, 6E, 8E)-3,7-二甲基-9-(2,6,6-三甲基环己基-1-烯基)nona-2,4,6,8-四烯酸。它是一种口服活性维甲酸衍生物,用于治疗严重难治性结节性痤疮。它的主要作用是减少皮脂腺的大小和皮脂的产生,从而改变皮肤表面的脂质组成。使用异维甲酸1-2mg/kg/天,3-4个月,痤疮患者炎性病变清除率达60%-95%。低至0.1mg/kg/天的剂量也被证明在清除病变方面是成功的。在少数酒渣鼻患者中也看到了令人鼓舞的结果。在大多数接受异维甲酸治疗的患者中,会出现影响皮肤粘膜系统的副作用和血清甘油三酯水平升高。异维甲酸在有生育能力的妇女中是严格禁忌的。本文讨论并解释了异维甲酸的名称及其物理和化学特性。它还包括制备方法,热学和光谱行为,分析方法和药理学。
{"title":"Isotretinoin.","authors":"Nasr Y Khalil,&nbsp;Ibrahim A Darwish,&nbsp;Abdulmohsen A Al-Qahtani","doi":"10.1016/bs.podrm.2019.10.005","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.005","url":null,"abstract":"<p><p>Isotretinoin is chemically named as: (2Z, 4E, 6E, 8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid. It is an orally active retinoic acid derivative for the treatment of severe refractory nodulocystic acne. It acts primarily by reducing sebaceous gland size and sebum production, and as a result alters skin surface lipid composition. Using isotretinoin for 1-2mg/kg/day for 3-4 months produces 60%-95% clearance of inflammatory lesions in patients with acne. Doses as low as 0.1mg/kg/day have also proven successful in the clearance of lesions. Encouraging results have also been seen in small numbers of patients with rosacea, Side effects affecting the mucocutaneous system and raised serum triglyceride levels occur in most patients receiving isotretinoin. Isotretinoin is strictly contraindicated in women of childbearing potential. This profile discusses and explains names of isotretinoin, its physical and chemical characteristics. It also includes methods of preparation, thermal and spectral behavior, methods of analysis, and pharmacology.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"45 ","pages":"119-157"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37732547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Profiles of drug substances, excipients, and related methodology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1